NAMSA is the World’s leading medtech cro offering global end-to-end development services

DRIVEN BY ITS GLOBAL REGULATORY EXPERTISE AND IN-DEPTH THERAPEUTIC KNOWLEDGE

FROM CONCEPT TO POST-MARKET, DELIVERING SIGNIFICANT TIME SAVINGS COMPARED TO INDUSTRY AVERAGES

HELPING medical device SPONSORS IMPROVE HEALTHCARE SINCE 1967

Our Services

Driven by our global regulatory expertise and in-depth therapeutic knowledge, NAMSA is a medical CRO offering only the most proven solutions to move your medical device through the development lifecycle as efficiently and cost-effectively as possible.

As a medical contract research organization, we are dedicated to helping you achieve accelerated, successful development and commercialization outcomes. NAMSA’s offerings include medical device testing; regulatory, reimbursement and quality consulting; and clinical research services.

Learn More

Product Development Strategy

Medical Device Testing

Clinical Research

Regulatory & Quality

Reimbursement

IVD

NAMSA APEX Program™

Therapeutic Expertise

White Papers Events & Webinars Test Navigator

Resources

Learn from the world’s leading medical CRO with complimentary access to our latest white papers, webinars, and other resources to learn proven strategies and best practices for successful medical device development and commercialization outcomes.

Browse All Resources

Blog

Always on the pulse of industry news, we interpret the latest regulatory guidelines and other medical device updates so you don’t have to. Learn from the world’s most trusted medical device CRO to stay up-to-date on recent news and what it means for your medical device development plans and commercial operations.

Access Now

March 27, 2023

NAMSA Expands MedTech Portfolio in Market Intelligence and Customer Research Services through its Acquisition of EU-Based SUAZIO

NAMSA announced today its acquisition of SUAZIO, an EU-based strategic consultancy providing global market research services to medical device and IVD developers.

March 08, 2023

UK MHRA Advisory Group Publishes Proposals

On 7 March, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) published the minutes of their Advisory Group, recommending ten (10) specific proposals to International Recognition, Routes for Innovation and System Capacity.

February 22, 2023

European Parliament to Amend MDR/IVDR Transitional Provisions

On 16 February 2023, the European Parliament voted to adopt an amendment that affects Article 120 and Article 110 of Regulations (EU) 2017/745 and (EU) 2017/746, respectively. The amendment only extends the transitional period for legacy medical devices, but also removes the sell-off period for both medical and in vitro diagnostic (IVD) devices.

February 08, 2023

U.S. FDA Emergency Use Authorization: CRO Lessons Learned for the MedTech Industry

During the COVID-19 Pandemic, the FDA CDRH put the hardest, longest and most intensive work into reviewing EUA applications for COVID-19 diagnostic tests. The result was a shift in how the FDA, MedTech manufacturers and CROs conduct work, which is still in place today.

January 18, 2023

Health Canada and FDA eSTAR Pilot

On January 10, 2023, the U.S. Food and Drug Administration (FDA) and Health Canada announced a new joint pilot program. This program will conduct tests on the use of FDA’s eSTAR to make a single medical device submission to both FDA and Health Canada.

HAVE QUESTIONS?

Let NAMSA’s medical device development experts guide you in the right direction.

Visit FAQ Contact Us

Join the NAMSA Network

Update your profile, post comments on the blog; sign-up for events, webinars and classes; receive email alerts and more.

Already have an account?
Please

NAMSA Client Portal

Client Portal